In this article, we will discuss Ramucirumab (1). So, let’s get started.
Indications
Gastric Cancer
Ramucirumab as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.